Compare KITT & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITT | GRI |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.5M |
| IPO Year | 2021 | 2020 |
| Metric | KITT | GRI |
|---|---|---|
| Price | $0.69 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | 452.6K | ★ 817.2K |
| Earning Date | 04-16-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,434,959.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 33.10 | N/A |
| 52 Week Low | $0.39 | $0.18 |
| 52 Week High | $4.48 | $6.70 |
| Indicator | KITT | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 51.80 |
| Support Level | $0.46 | $0.20 |
| Resistance Level | $1.03 | $2.53 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 16.85 | 21.06 |
Nauticus Robotics Inc is a technology-driven company specializing in the development of fully electric autonomous robotic solutions for subsea applications. Its portfolio includes autonomous underwater vehicles (AUVs), electric robotic manipulators, a platform-agnostic robotic operating system, and related engineering, consulting and prototype services. The Company's solutions enable autonomous operations for both commercial and defense sectors, with alignment to offshore energy and national security interests. Its addressable markets include upstream, midstream and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research and subsea mining, with current focus on oil and gas operations and defense applications.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.